<DOC>
	<DOCNO>NCT00358501</DOCNO>
	<brief_summary>The purpose study ( 1 ) demonstrate efficacy safety ( toxicity ) 25 mg/kg/day Defibrotide patient severe veno-occlusive disease ( sVOD ) ( 2 ) evaluate serum endothelial marker veno-occlusive disease ( VOD ) analysis blood sample .</brief_summary>
	<brief_title>Defibrotide Treatment Severe Hepatic Veno-Occlusive Disease Hematopoetic Stem Cell Transplant Patients</brief_title>
	<detailed_description>This historically-controlled , multicenter , open label Phase 3 study determine safety efficacy 25 mg/kg/day Defibrotide ( DF ) treatment severe VOD hematopoietic stem cell transplantation ( HSCT ) patient . In study , term `` severe VOD '' define patient meet Baltimore diagnostic criterion VOD ( total bilirubin &gt; /= 2.0 mg/dL plus two following : ascites , &gt; /=5 % weight gain hepatomegaly ) , also multi-organ failure ( i.e. , pulmonary and/or renal dysfunction ) . This represent group patient mortality Day+100 estimate &gt; 80 % . Comparisons : The primary parameter Complete Response 100 day follow stem cell transplant , utilize historical control comparator . The historical control database generate retrospective medical chart review perform participating center ; survival outcome patient would otherwise meet eligibility criterion trial compare survival observed patient prospectively treat Defibrotide . Secondary parameter include survival rate 100 day 6 month post stem cell transplantation ( SCT ) , special study endothelial serum marker VOD . This study ass safety dose schedule setting .</detailed_description>
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Clinical diagnosis VOD , define jaundice ( bilirubin &gt; /= 2 mg/dL ) least 2 follow clinical finding , Day+21 post stem cell transplant : ascites ; weight gain &gt; /= 5 % baseline weight ; hepatomegaly . Severe VOD , define VOD multiorgan failure , i.e. , presence one following , Day+28 post stem cell transplant : renal pulmonary dysfunction . Provide voluntary write informed consent . Preexisting ( prior SCT ) cirrhosis An alternative diagnosis weight gain , ascites jaundice Graftversushost disease ( GVHD ) grade B high involve liver gut grade C high involve skin Prior solid organ transplant Dependent dialysis prior and/or time SCT Dependent oxygen supplementation prior SCT Significant acute bleed hemodynamic instability Requirement use medication increase risk hemorrhage exclude treatment group</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Defibrotide</keyword>
	<keyword>Severe veno occlusive disease</keyword>
	<keyword>Multi organ failure</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Liver</keyword>
	<keyword>Regimen relate toxicity</keyword>
	<keyword>Day 100 survival</keyword>
</DOC>